The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal ...

The 340B Program has continued to undergo significant upheaval in 2024 that has the potential to bring about impactful changes to how the 340B Program operates moving forward. These developments have ...

Senator calls on Congress to increase oversight of the 340B Drug Pricing Program by requiring participating providers to complete annual reports on program savings and revenues. If your health system ...

The 340B program spent $43.9 billion in 2021, supporting nearly 50,000 hospitals with discounted outpatient drugs. Cancer drugs constitute 41% of 340B purchases, with outpatient departments and ...

The 340B program, intended to lower drug costs for low-income patients, often benefits hospitals more than patients. A lack of transparency allows some hospitals to profit from the program instead of ...

Drug companies are at it again. They will not relent in their multiyear campaign to dismantle the 340B Drug Pricing Program. Drug companies are at it again. They will not relent in their multiyear ...

In the final days of 2024, three pharmaceutical giants sued the federal government. In their joint lawsuit, Amgen, Eli Lilly and Company, and UCB claim several Nevada STD clinics were unlawfully ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

Every Illinoisan deserves access to affordable quality health care close to home, including medication. That’s why I fully support legislation in Springfield that protects the federal 340B drug ...